View Item 

Show simple item record

Differential Effects of Raloxifene and Estrogen on Insulin Sensitivity in Postmenopausal Women
dc.contributor.authorLee, Cathy C.en_US
dc.contributor.authorKasa-Vubu, Josephine Z.en_US
dc.contributor.authorSupiano, Mark A.en_US
dc.date.accessioned2010-04-01T14:55:55Z
dc.date.available2010-04-01T14:55:55Z
dc.date.issued2003-05en_US
dc.identifier.citationLee, Cathy C.; Kasa-Vubu, Josephine Z.; Supiano, Mark A. (2003). "Differential Effects of Raloxifene and Estrogen on Insulin Sensitivity in Postmenopausal Women." Journal of the American Geriatrics Society 51(5): 683-688. <http://hdl.handle.net/2027.42/65389>en_US
dc.identifier.issn0002-8614en_US
dc.identifier.issn1532-5415en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/65389
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=12752845&dopt=citationen_US
dc.description.abstractTo test the hypothesis that both raloxifene and estrogen would improve insulin sensitivity in postmenopausal women and that the magnitude of the effect would be similar for both drugs. DESIGN: Placebo-controlled, double-blind, randomized study. SETTING: The General Clinical Research Center of the University of Michigan Medical Center, a university hospital. PARTICIPANTS: Forty-four healthy postmenopausal women 73 ± 7 years old (mean age ± standard deviation) who were not receiving hormone replacement therapy. INTERVENTION: Eight weeks of drug therapy with randomization to raloxifene (n = 16), estrogen (n = 14), or placebo (n = 14). MEASUREMENTS: These subjects underwent a frequently sampled intravenous glucose tolerance test to determine insulin sensitivity (S I ) and total and regional (central) body composition measurements by dual-energy x-ray absorptiometry at baseline and after 8 weeks of drug therapy. RESULTS: There were no statistically significant differences in age, body mass index, total or central fat mass, or S I between the three groups at baseline. The major outcome variable was S I . After 8 weeks of drug therapy, there was no significant change in S I in the placebo group or in the estrogen group and a significant decrease in S I in the raloxifene group, P = .003. CONCLUSION: In contrast to estrogen's ability to maintain insulin sensitivity, raloxifene decreases insulin sensitivity in healthy nondiabetic postmenopausal women. The clinical significance of this effect of raloxifene to impair insulin sensitivity in postmenopausal women warrants further evaluation in future studies.en_US
dc.format.extent88206 bytes
dc.format.extent3110 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Science Incen_US
dc.rights2003 American Geriatrics Societyen_US
dc.subject.otherRaloxifeneen_US
dc.subject.otherInsulin Sensitivityen_US
dc.subject.otherPostmenopausal Womenen_US
dc.titleDifferential Effects of Raloxifene and Estrogen on Insulin Sensitivity in Postmenopausal Womenen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelGeriatricsen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationum* University of Michigan Health System, Ann Arbor, Michigan; anden_US
dc.contributor.affiliationumVA Ann Arbor Healthcare Systems, Ann Arbor, Michigan.en_US
dc.identifier.pmid12752845en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/65389/1/j.1600-0579.2003.00214.x.pdf
dc.identifier.doi10.1034/j.1600-0579.2003.00214.xen_US
dc.identifier.sourceJournal of the American Geriatrics Societyen_US
dc.identifier.citedreferenceMcKerns KW, Coulomb B, Kaleita E et al. Some effects of in vivo administered estrogens on glucose metabolism and adrenal cortical secretion in vitro. Endocrinology 1958 ; 63 : 709 – 722.en_US
dc.identifier.citedreferenceCostrini NV, Kalkhoff RK. Relative effects of pregnancy, estradiol, and progesterone on plasma insulin and pancreatic islet insulin secretion. J Clin Invest 1971 ; 50 : 992 – 999.en_US
dc.identifier.citedreferenceBailey CJ, Ahmed-Sorour H. Role of ovarian hormones in the long-term control of glucose homeostasis. Diabetologia 1980 ; 19 : 475 – 481.en_US
dc.identifier.citedreferenceBarrett-Connor E, Laakso M. Ischemic heart disease risk in postmenopausal women. Effects of estrogen use on glucose and insulin levels. Arteriosclerosis 1990 ; 10 : 531 – 534.en_US
dc.identifier.citedreferenceHammond CB, Jelovsek FR, Lee KL et al. Effects of long-term estrogen replacement therapy. Am J Obstet Gynecol 1979 ; 133 : 525 – 536.en_US
dc.identifier.citedreferenceNotelovitz M, Johnston M, Smith S et al. Metabolic and hormonal effects of 25-mg and 50-mg 17β-estradiol implants in surgically menopausal women. Obstet Gynecol 1987 ; 70 : 749 – 754.en_US
dc.identifier.citedreferenceSpellacy WN, Buhi WC, Birk SA. The effect of estrogens on carbohydrate metabolism: Glucose, insulin, and growth hormone studies on one hundred and seventy-one women ingesting Premarin, mestranol, and ethinyl estradiol for six months. Am J Obstet Gynecol 1972 ; 114 : 378 – 392.en_US
dc.identifier.citedreferenceCagnacci A, Soldani R, Carriero PL et al. Effects of low doses of transdermal 17β-estradiol on carbohydrate metabolism in postmenopausal women. J Clin Endocrinol Metab 1992 ; 74 : 1396 – 1400.en_US
dc.identifier.citedreferenceAjabor LN, Tsai CC, Vela P et al. Effect of exogenous estrogen on carbohydrate metabolism in postmenopausal women. Am J Obstet Gynecol 1972 ; 113 : 383 – 387.en_US
dc.identifier.citedreferenceGodsland IF, Gangar K, Walton C et al. Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism 1993 ; 42 : 846 – 853.en_US
dc.identifier.citedreferenceLindheim SR, Presser SC, Ditkoff EC et al. A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. Fertil Steril 1993 ; 60 : 664 – 667.en_US
dc.identifier.citedreferenceLindheim SR, Buchanan TA, Duffy DM et al. Comparison of estimates of insulin sensitivity in pre- and postmenopausal women using the insulin tolerance test and the frequently sampled intravenous glucose tolerance test. J Soc Gynecol Invest 1994 ; 1 : 150 – 154.en_US
dc.identifier.citedreferenceWillhite SL, Goebel SR, Scoggin JA. Raloxifene provides an alternative for osteoporosis prevention. Ann Pharmacother 1998 ; 32 : 834 – 837.en_US
dc.identifier.citedreferenceHulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998 ; 280 : 605 – 613.en_US
dc.identifier.citedreferenceKauffman RF, Bensch WR, Roudebush RE et al. Hypocholesterolemic activity of raloxifene (LY139481): Pharmacological characterization as a selective estrogen receptor modulator. J Pharmacol Exp Ther 1997 ; 280 : 146 – 153.en_US
dc.identifier.citedreference16. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1998 ; 21 ( Suppl. 1 ): S5 – S19.en_US
dc.identifier.citedreferenceLindheim SR, Presser SC, Ditkoff EC et al. A possible bimodal effect of estrogen in insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. Menopause 1993 ; 60 : 664 – 667.en_US
dc.identifier.citedreferenceBergman R. Toward physiological understanding of glucose tolerance: Minimal model approach. Diabetes 1989 ; 38 : 1512 – 1527.en_US
dc.identifier.citedreferenceYang Y, Youn J, Bergman R. Modified protocols improve insulin sensitivity estimation using the minimal model. Am J Physiol 1987 ; 253 : E595 – E602.en_US
dc.identifier.citedreferenceFerrari P, Alleman Y, Shaw S et al. Reproducibility of insulin sensitivity by the minimal model method. Diabetologia 1991 ; 34 : 527 – 530.en_US
dc.identifier.citedreferenceBergman R, Prager R, Volund A et al. Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. J Clin Invest 1987 ; 79 : 790 – 800.en_US
dc.identifier.citedreferenceMazess R, Barden H, Bisek J et al. Dual-energy x-ray absorptiometry for total-body and regional bone-mineral and soft-tissue composition. Am J Clin Nutr 1990 ; 51 : 1106 – 1112.en_US
dc.identifier.citedreferenceWilke TJ, Utley DJ. Total testosterone, free-androgen index, calculated free testosterone, and free testosterone by analog RIA compared in hirsute women and in otherwise-normal women with altered sex-hormone-binding-globulin. Clin Chem 1987 ; 33 : 1372 – 1375.en_US
dc.identifier.citedreferenceSupiano MA, Hogikyan RV, Morrow LA et al. Hypertension and insulin resistance: Role of sympathetic nervous system activity. Am J Physiol 1992 ; 263 : E935 – E942.en_US
dc.identifier.citedreferenceEttinger B, Black D, Mitlak BH et al. Reduction of vertebral fracture risk in a postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. JAMA 1999 ; 282 : 637 – 645.en_US
dc.identifier.citedreferenceDelmas PD, Bjarnason NH, Mitlak BH et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997 ; 337 : 1641 – 1647.en_US
dc.identifier.citedreferenceAndersson B, Johannsson G, Holm G et al. Raloxifene does not affect insulin sensitivity or glycemic control in postmenopausal women with type 2 diabetes mellitus: A randomized clinical trial. J Clin Endocrinol Metab 2002 ; 87 : 122 – 128.en_US
dc.identifier.citedreferenceOleksik AM, Duong T, Pliester N et al. Effects of the selective estrogen receptor modulator raloxifene on the somatotropic axis and insulin-glucose homeostasis. J Clin Endocrinol Metab 2001 ; 86 : 2763 – 2768.en_US
dc.identifier.citedreferenceAnderson DC. Sex-hormone-binding globulin. Clin Endocrinol 1974 ; 3 : 69 – 96.en_US
dc.identifier.citedreferenceHaffner SM, Valdez RA, Morales PA et al. Decreased sex hormone-binding globulin predicts noninsulin-dependent diabetes mellitus in women but not in men. J Clin Endocrinol Metab 1993 ; 77 : 56 – 60.en_US
dc.identifier.citedreferenceLinstedt G, Lundberg P-A, Lapidus L et al. Low sex-hormone-binding globulin concentration as independent risk factor for development of NIDDM, 12-yr follow-up of population study of women in Gothenburg, Sweden. Diabetes 1991 ; 40 : 123 – 128.en_US
dc.identifier.citedreferenceNestler JE, Powers LP, Matt DW et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1991 ; 72 : 83 – 89.en_US
dc.identifier.citedreferencePlymate SR, Matej LA, Jones RE et al. Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. J Clin Endocrinol Metab 1988 ; 67 : 460 – 464.en_US
dc.identifier.citedreferenceNestler JE, Clore JN, Strauss JF III et al. The effects of hyperinsulinemia on serum testosterone, progesterone, dehydroepiandrosterone sulfate, and cortisol levels in normal women and in a woman with hyperandrogenism, insulin resistance, and acanthosis nigricans. J Clin Endocrinol Metab 1987 ; 64 : 180 – 184.en_US
dc.identifier.citedreferenceBarkhem T, Carlsson B, Nilsson Y et al. Differential response of estrogen receptor α and estrogen receptor β to partial agonists/antagonists. Mol Pharmacol 1998 ; 54 : 105 – 112.en_US
dc.identifier.citedreferencePaech K, Webb P, Kuiper GGJM et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta and AP1 sites. Science 1997 ; 277 : 1508 – 1510.en_US
dc.identifier.citedreferenceYang NN, Venugopalan M, Hardikar S et al. Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene. Science 1996 ; 273 : 1222 – 1225.en_US
dc.identifier.citedreferenceGrese TA, Sluka JP, Bryant HU et al. Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc Natl Acad Sci U S A 1997 ; 94 : 14105 – 14110.en_US
dc.identifier.citedreferenceKhovidhunkit W, Shoback D. Clinical effects of raloxifene hydrochloride in women. Ann Intern Med 1999 ; 130 : 431 – 439.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1600-0579.2003.00214.x.pdf
Size:
86.13KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.